Friday, July 10, 2026

pharma · Major Depressive Disorder (MDD) · Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

Talon Biomarkers

Talion is a pharma organization headquartered in JP. Primary therapeutic focus areas include Major Depressive Disorder (MDD), Primary or advanced breast cancer LumA or ER+ Lobular subtypes., non-small cell lung cancer (N

Whippany, USA HQ
2021 Founded
7 Employees
PMDA registrant Type
Company details
Status
Public
HQ
Whippany, USA
Founded
2021
Employees
7
Programs
5
Drugs
44
Patents
0

Quick answer

Talion is a pharma organization headquartered in JP. Primary therapeutic focus areas include Major Depressive Disorder (MDD), Primary or advanced breast cancer LumA or ER+ Lobular subtypes., non-small cell lung cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer. NovaPharmaNews links 5 clinical program(s), 33 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (3), phase 3 (2).

Company snapshot

Talon Biomarkers is a biomarker discovery engine built to capture indicators of disease and therapy from a sea of immune cells. We're fueled by a uniquely powerful and robust technology platform that changes the old-school paradigm of how a contract-research organization works. We are your partners in science, helping with experimental and study design, data acquisition, analysis, and even interpr

  • 1 approved product(s) across US/EU regulatory metadata.
  • 5 active pipeline program(s) linked via ClinicalTrials.gov.
  • 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Talon Biomarkers. Not investment advice.

Active clinical programs

  • PRIN - 20227EA9AN Major Depressive Disorder (MDD)
    Phase 3
  • PRIN - 20227EA9AN Major Depressive Disorder (MDD)
    Phase 3
  • - Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
    Phase 2
  • CIBI3009A101 Extensive-Stage Small Cell Lung Cancer
    Phase 2

Momentum

Proprietary activity score for Talon Biomarkers.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Talon Biomarkers.

  1. Clinical update

    CIBI3009A101 — Phase 2

  2. Clinical update

    PRIN - 20227EA9AN — Phase 3

  3. Clinical update

    PRIN - 20227EA9AN — Phase 3

  4. Clinical update

    Hyperbolic — Phase 2

  5. Clinical update

    - — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Talon Biomarkers?

    Talion is a pharma organization headquartered in JP. Primary therapeutic focus areas include Major Depressive Disorder (MDD), Primary or advanced breast cancer LumA or ER+ Lobular subtypes., non-small cell lung cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer. NovaPharmaNew

  • Is Talon Biomarkers publicly traded?

    Talon Biomarkers appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Talon Biomarkers develop or market?

    We link 44 drug profile(s) where Talon Biomarkers is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vita-europe-limited#company-drugs.

  • What are the latest developments for Talon Biomarkers?

    In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Talon Biomarkers focus on?

    Talon Biomarkers focuses on Major Depressive Disorder (MDD), Primary or advanced breast cancer LumA or ER+ Lobular subtypes., non-small cell lung cancer (NSCLC) based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Oncology
6
Others
5
Neurology
1